CA
NZ
UK
AU
IND
US
No company release dated October 19, 2026 explains the gain. The context is a run of analyst notes: Barclays kept Buy with a USD 122 target on October 7, RBC cut to USD 75 from USD 85 on October 8, UBS assumed coverage with …
No same-day catalyst was found for October 19, when Centene (NYSE:CNC) slipped 0.77% to USD 68.63. The recent lift came on October 13, when shares closed up 2.8% at USD 68.88 and had gained about 6.6% across the days that followed news of a …
The catalyst is a burst of new analyst coverage. Jefferies initiated on October 16 with a Buy rating and a USD 47 target, citing a leading position in occupational health, high return on capital and a stable reimbursement structure, and Stephens started on October …
No same-day catalyst was found for October 19, when Centene (NYSE:CNC) slipped 0.77% to USD 68.63. The recent lift came on October 13, when shares closed up 2.8% at USD 68.88 and had gained about 6.6% across the days that followed news of a …
AirSculpt Technologies (NASDAQ:AIRS) shares were trading near their 52-week low at USD 1.20 on October 19, 2026, down 6.27%. The body contouring provider's latest filings are dominated by its term loan: a fourth amendment signed August 7 pushed the maturity out to November 2027 …
Apnimed (NASDAQ:APMD) shares were trading near their 52-week low at USD 16.74 on October 19, 2026, down 5.74%. The Cambridge, Massachusetts, company began trading on July 31 and reported its first quarterly results as a public company on September 8. They paired a $125.9 …
Ardelyx (NASDAQ:ARDX) shares were trading near their 52-week low at USD 3.10 on October 19, 2026, up 0.16%. The commercial-stage biopharmaceutical company, which sells IBSRELA and XPHOZAH, reported higher second quarter sales, lower full-year IBSRELA revenue guidance and a refinanced loan facility. One large …
Avalo (NASDAQ:AVTX) shares were trading near their 52-week low at USD 11.56 on October 19, 2026, an increase of 2.53%. The clinical-stage biotech has no revenue, but it reported $472.2 million of cash and investments at June 30, after a May equity offering that …
Anavex Life Sciences (NASDAQ:AVXL) shares were trading near their 52-week low at USD 1.23 on October 19, 2026, down 6.49%. Since midyear, the clinical-stage biotechnology company has filed amended reports on internal controls, regained compliance with a Nasdaq filing rule, held a contested annual …
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) shares were trading near their 52-week low at USD 2.83 on October 19, 2026, up 0.35%. The clinical-stage company develops oral small-molecule therapies for RAS-pathway cancers. It released new data for its BBO-8520 KRAS G12C program on September 8 and …
Please wait processing your request...